<DOC>
	<DOCNO>NCT00004109</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness doxorubicin plus external-beam radiation therapy treat patient soft tissue sarcoma .</brief_summary>
	<brief_title>Doxorubicin Plus External-Beam Radiation Therapy Treating Patients With Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity maximum tolerate dose doxorubicin combine external beam radiotherapy patient high risk soft tissue sarcoma extremity trunk . II . Assess radiographic pathologic response rate preoperative regimen subset patient measurable disease . OUTLINE : This dose escalation study doxorubicin . Patients receive doxorubicin intravenous ( IV ) bolus follow immediately doxorubicin IV 4 day every week 5 week absence unacceptable toxicity . Patients measurable disease receive external beam radiotherapy 5 day week 5 week concurrently doxorubicin treatment . Patients measurable disease undergo surgical resection residual mass 4-7 week follow completion chemoradiation . Patients measurable disease undergone prereferral excision undergo surgical resection prior surgical scar tumor bed followed external beam radiotherapy 5 day week 5 week . Cohorts 3 patient receive escalate dos doxorubicin maximum tolerate dose ( MTD ) determine . Patients follow every 3 month 3 year , every 4 month 2 year , annually 5 year . PROJECTED ACCRUAL : A maximum 30 patient accrue study rate 5-6 patient per month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Patients must cytologic histologic proof large ( &gt; 5 mc ) , Grade III , resectable soft tissue sarcoma extremity trunk ( AJCC Stage IIIB ) . Patients The American Joint Committee Cancer ( AJCC ) Stage IIB tumor ( Grade II ) great 8 cm also eligible . 2 . Patients may measurable nonmeasurable disease ( C/P prereferral excision ) . 3 . Patients may prior doxorubicin ( total doxorubicin dose 450 mg/m2 ) . 4 . Patients may prior history malignancy ( discretion Principal Investigator ) . 5 . Patients must Karnofsky Point Scale ( P.S . ) &gt; &gt; 70 Xubrod P.S . 0 1 . 6 . Patients must : Absolute neutrophil count ( ANC ) &gt; 1,500 cells/mm ; platelet count &gt; 100,000 platelets/ml ; serum creatinine &lt; 1.8 mg/dl , aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) &lt; 3 time normal , total bilirubin &lt; 1.5mg/dl ; patient cumulative Adriamycin 450 mg/M2 , EF &gt; 50 % . 7 . Women childbearing potential must pregnant breast feeding must practice adequate contraception . 1 . Patients must prior radiation therapy ( XRT ) area primary tumor , anticipated XRT field must include perineum , scrotum , vaginal introitus . 2 . Patients uncontrolled coexist medical condition exclude . 3 . Patient must pregnant brest feeding .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>External-Beam RT</keyword>
	<keyword>XRT</keyword>
	<keyword>cancer</keyword>
	<keyword>PREOPERATIVE CONCURRENT CHEMORADIATION</keyword>
	<keyword>EXTREMITY SOFT TISSUE SARCOMAS</keyword>
	<keyword>TRUNK SOFT TISSUE SARCOMAS</keyword>
	<keyword>Concurrent Chemoradiation</keyword>
	<keyword>Surgical Resection</keyword>
	<keyword>Localized Extremity Soft Tissue Sarcomas</keyword>
	<keyword>Body Wall Soft Tissue Sarcomas</keyword>
</DOC>